Filing Flows › Ovid Therapeutics (OVID) › Q4 2025
Ovid Therapeutics (OVID) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 18, 2026
Ovid Therapeutics (OVID) reported revenue of $718K for the fourth quarter 2025 (Q4 2025), +845% from a year earlier and +444% from the quarter before.
Ovid Therapeutics, Q4 2025: revenue $718K (+845% year over year), net earnings $9.7M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $718K | +444% | +845% |
| Operating profit | −$12.3M | — | — |
| Net earnings | $9.7M | — | — |
| Operating cash flow | −$10.4M | — | — |
What changed
Revenue was $718K in Q4 2025, up 845% year over year and up 444% from the previous quarter.
Operating costs exceeded revenue by $12.3M, an operating margin of -1712.1%. Total costs grew 20% against revenue growth of 845%. The fastest-growing cost line was General & admin (+32%). Net earnings were $9.7M. The effective tax rate was 0.0%. Non-operating items added $22.0M, 227% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$10.4M. Non-cash charges added back $17K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items used $21.3M.
Questions
What was Ovid Therapeutics' revenue in the fourth quarter 2025?
Ovid Therapeutics (OVID) reported revenue of $718K for the fourth quarter 2025 (Q4 2025), +845% from a year earlier and +444% from the quarter before.
Source: Ovid Therapeutics 10-K on SEC EDGAR.